Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vagina | 7 | 2016 | 31 | 2.360 |
Why?
|
| Lactobacillus | 7 | 2016 | 15 | 2.010 |
Why?
|
| Glycogen | 6 | 2016 | 12 | 1.970 |
Why?
|
| Vaginosis, Bacterial | 5 | 2014 | 16 | 1.290 |
Why?
|
| Microbiota | 4 | 2016 | 65 | 1.050 |
Why?
|
| HIV Infections | 6 | 2016 | 424 | 0.940 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 3 | 2012 | 12 | 0.810 |
Why?
|
| Progesterone | 2 | 2016 | 20 | 0.610 |
Why?
|
| Estrogens | 2 | 2016 | 26 | 0.610 |
Why?
|
| Premenopause | 2 | 2016 | 11 | 0.590 |
Why?
|
| Immunity, Innate | 3 | 2014 | 54 | 0.530 |
Why?
|
| Body Fluids | 1 | 2016 | 13 | 0.500 |
Why?
|
| Postmenopause | 1 | 2015 | 57 | 0.460 |
Why?
|
| Genitalia, Female | 2 | 2013 | 13 | 0.440 |
Why?
|
| Metagenome | 2 | 2012 | 15 | 0.440 |
Why?
|
| Cervix Uteri | 1 | 2014 | 12 | 0.430 |
Why?
|
| Trichomonas vaginalis | 2 | 2013 | 3 | 0.400 |
Why?
|
| HIV-1 | 2 | 2012 | 202 | 0.390 |
Why?
|
| Trichomonas Vaginitis | 1 | 2012 | 2 | 0.380 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 42 | 0.370 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2011 | 2 | 0.370 |
Why?
|
| Fatty Acids, Volatile | 1 | 2011 | 26 | 0.360 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 26 | 0.360 |
Why?
|
| Lactic Acid | 1 | 2011 | 5 | 0.360 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2011 | 11 | 0.350 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2010 | 2 | 0.340 |
Why?
|
| Cytokines | 1 | 2011 | 213 | 0.330 |
Why?
|
| Female | 12 | 2016 | 13124 | 0.310 |
Why?
|
| Humans | 13 | 2016 | 23331 | 0.240 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 130 | 0.230 |
Why?
|
| Adult | 6 | 2016 | 7070 | 0.190 |
Why?
|
| Mucous Membrane | 2 | 2014 | 24 | 0.190 |
Why?
|
| Disease Susceptibility | 2 | 2012 | 56 | 0.180 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 48 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2014 | 39 | 0.130 |
Why?
|
| Tenofovir | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cyclohexanes | 1 | 2016 | 2 | 0.130 |
Why?
|
| CD4-CD8 Ratio | 1 | 2016 | 4 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 49 | 0.130 |
Why?
|
| Triazoles | 1 | 2016 | 29 | 0.130 |
Why?
|
| Middle Aged | 4 | 2016 | 8055 | 0.120 |
Why?
|
| Animals | 3 | 2012 | 3287 | 0.120 |
Why?
|
| Dysbiosis | 1 | 2016 | 34 | 0.120 |
Why?
|
| Anti-HIV Agents | 1 | 2016 | 60 | 0.120 |
Why?
|
| Cervix Mucus | 1 | 2015 | 4 | 0.120 |
Why?
|
| Menstrual Cycle | 1 | 2015 | 19 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 37 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 79 | 0.120 |
Why?
|
| Osteoporosis | 1 | 2016 | 72 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2016 | 69 | 0.110 |
Why?
|
| Macaca nemestrina | 2 | 2012 | 2 | 0.110 |
Why?
|
| Inflammation | 1 | 2016 | 235 | 0.110 |
Why?
|
| Base Sequence | 1 | 2014 | 101 | 0.110 |
Why?
|
| alpha-Amylases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Epithelium | 1 | 2014 | 26 | 0.110 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 41 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2014 | 48 | 0.110 |
Why?
|
| Trichomonas Infections | 1 | 2013 | 2 | 0.100 |
Why?
|
| Interleukins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2013 | 15 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 12 | 0.100 |
Why?
|
| Macaca | 1 | 2012 | 2 | 0.090 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 37 | 0.090 |
Why?
|
| Young Adult | 2 | 2014 | 1674 | 0.090 |
Why?
|
| Adolescent | 2 | 2014 | 1916 | 0.090 |
Why?
|
| Ligands | 1 | 2011 | 39 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 50 | 0.090 |
Why?
|
| HIV Antibodies | 1 | 2011 | 14 | 0.090 |
Why?
|
| Women | 1 | 2011 | 13 | 0.090 |
Why?
|
| Macaca mulatta | 1 | 2011 | 56 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 106 | 0.090 |
Why?
|
| Neutrophils | 1 | 2011 | 94 | 0.090 |
Why?
|
| Symbiosis | 1 | 2010 | 2 | 0.090 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 17 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2010 | 31 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2011 | 481 | 0.080 |
Why?
|
| Risk Factors | 1 | 2012 | 1998 | 0.060 |
Why?
|
| Male | 2 | 2016 | 12629 | 0.040 |
Why?
|
| Darunavir | 1 | 2016 | 1 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2016 | 2 | 0.030 |
Why?
|
| Placebos | 1 | 2016 | 64 | 0.030 |
Why?
|
| Education | 1 | 2016 | 31 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 25 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 104 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2016 | 79 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2016 | 102 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 382 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 7 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 565 | 0.030 |
Why?
|
| beta-Defensins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cathelicidins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2013 | 2 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2012 | 46 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 1523 | 0.020 |
Why?
|
| United States | 1 | 2016 | 1829 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1050 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 2988 | 0.020 |
Why?
|